12:00 AM
 | 
Mar 10, 2014
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Synta preclinical data

In mouse xenograft tumor models, STA-12-8666 safely delivered >10 times greater levels of SN-38, the active metabolite of irinotecan, vs. the maximum tolerated dose (MTD) of unconjugated irinotecan. Compared to the MTD of 50 mg/kg unconjugated irinotecan, STA-12-8666 significantly reduced tumor volume at a...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >